ZYF0033

Overview

ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a + CD8 + T cells, but not T cells, PD-1 + CD8 + T cells, TIM-3 + CD8 + Infiltration of T cells and LAG3 + CD8 + T cells was reduced.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Obesity | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > MAP4K

Product Information

• Catalog No.: HY-144088
• CAS No.: 2380300-79-6
• Molecular Formula: C26H30N4O2S
• Molecular Weight: 462.61
• Purity: 98.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 4 mg/mL (8.65 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source